Authors
Clarke, Noel WAffiliation
Department of Urology, The Christie and Salford Royal Hospitals, Manchester, UK.Issue Date
2022
Metadata
Show full item recordCitation
Clarke NW. Following the Narrow Path. Eur Urol. 2022 Oct 18. PubMed PMID: 36270833. Epub 2022/10/22. eng.Journal
European UrologyDOI
10.1016/j.eururo.2022.09.027PubMed ID
36270833Additional Links
https://dx.doi.org/10.1016/j.eururo.2022.09.027Type
EditorialLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/j.eururo.2022.09.027
Scopus Count
Collections
Related articles
- Immunohistochemistry-based assessment of androgen receptor status and the AR-null phenotype in metastatic castrate resistant prostate cancer.
- Authors: Gupta S, Vanderbilt C, Abida W, Fine SW, Tickoo SK, Al-Ahmadie HA, Chen YB, Sirintrapun SJ, Chadalavada K, Nanjangud GJ, Bialik A, Morris MJ, Scher HI, Ladanyi M, Reuter VE, Gopalan A
- Issue date: 2020 Sep
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.
- Authors: Karantanos T, Corn PG, Thompson TC
- Issue date: 2013 Dec 5
- Androgen receptor enhancer amplification in matched patient-derived xenografts of primary and castrate-resistant prostate cancer.
- Authors: Porter LH, Bakshi A, Pook D, Clark A, Clouston D, Kourambas J, MURAL Investigators, Goode DL, Risbridger GP, Taylor RA, Lawrence MG
- Issue date: 2021 Jun
- Targeting the androgen receptor in metastatic castrate-resistant prostate cancer: A review.
- Authors: Anantharaman A, Friedlander TW
- Issue date: 2016 Aug
- Androgen receptors in hormone-dependent and castration-resistant prostate cancer.
- Authors: Shafi AA, Yen AE, Weigel NL
- Issue date: 2013 Dec